XNAS · Healthcare · Biotechnology
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.54 | -0.52 | +3.70% | $0 | ✅ Beat | +1.41% | -6.23% | — |
| 2026-03-16 | Q4 2025 | -0.52 | -0.50 | +3.85% | $0 | ✅ Beat | +1.29% | -15.84% | -0.66% |
| 2025-11-10 |
| Q3 2025 |
| -0.44 |
| -0.49 |
| -11.36% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.43 | -0.51 | -18.60% | $0 | ❌ Miss | +3.28% | +26.04% | +70.90% |
| 2025-05-13 | Q1 2025 | -0.50 | -0.36 | +28.00% | $0 | ✅ Beat | — | — | — |
| 2025-03-18 | Q4 2024 | 0.17 | -0.51 | -400.00% | $0 | ❌ Miss | — | — | — |
| 2024-11-12 | Q3 2024 | -0.57 | -0.60 | -5.26% | $0 | ❌ Miss | — | — | — |
| 2024-08-06 | Q2 2024 | -0.55 | -0.54 | +1.82% | $0 | ✅ Beat | — | — | — |
Showing last 8 quarters.